Alongside the current identification of occludin as a CatS target, it was noticed that a decorin-derived peptide specifically released by CatS was identified in the serum of patients with COPD and proposed as a potential COPD biomarker [74]. Here, DCN is linked to chronic obstructive pulmonary disease.